{"id":"W2406780605","doi":"10.1200/jco.2009.27.15_suppl.8039","title":"Final safety results of BO17704 (AVAiL): A phase III randomized study of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; McGill University Health Centre","funders":"","keywords":"Medicine; Neutropenia; Placebo; Internal medicine; Gemcitabine; Bevacizumab; Adverse effect; Clinical endpoint; Gastroenterology; Phases of clinical research; Surgery; Randomized controlled trial; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001925449,0.001026728,0.001677052,0.0003326747,0.0003457417,0.0008324705,0.0007002161,0.00119468,0.006330926],"category_scores_gemma":[0.001264005,0.0005301464,0.0009550123,0.0002931668,0.0009031215,0.000494744,0.0003713909,0.002602353,0.0009114553],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009926495,"about_ca_system_score_gemma":0.001589823,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001086898,"about_ca_topic_score_gemma":0.003037707,"domain_scores_codex":[0.9995135,0.0003169817,0.00002160181,0.00004899827,0.00005167669,0.00004722924],"domain_scores_gemma":[0.9992096,0.0002000557,0.0002124995,0.00003817457,0.00006200447,0.0002775852],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9012678,0.01306372,0.00329762,0.001389288,0.001459392,0.0001760374,0.0001456002,0.001357562,0.02453421,0.0002242257,0.006532206,0.04655233],"study_design_scores_gemma":[0.8368687,0.146126,0.006823496,0.00005649741,0.001049577,0.0002359984,0.00003497948,0.0008272682,0.003820204,0.0001257366,0.004005865,0.00002554816],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9851171,0.003882804,0.0007152249,0.0008046032,0.0001225171,0.002821566,0.003752491,0.000198798,0.002585018],"genre_scores_gemma":[0.9835739,0.002462385,0.001619989,0.0009528556,0.0001686508,0.002271585,0.005238103,0.00006170187,0.003650853],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006330926,"threshold_uncertainty_score":0.02117908,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04465509602666898,"score_gpt":0.4493318156673473,"score_spread":0.4046767196406783,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}